MannKind Corporation to Participate in H.C. Wainwright 23rd Annual Global Investment Conference

Rhea-AI Summary

MannKind Corporation (Nasdaq: MNKD) announced that CEO Michael Castagna, PharmD, will participate in a Fireside Chat at the H.C. Wainwright 23rd Annual Global Investment Conference, available on demand from September 13, 2021. Interested parties can access the webcast through the Company’s Events & Presentations section on their website, where a replay will be available for 14 days. MannKind focuses on developing inhaled therapeutic products for endocrine and orphan lung diseases, including Afrezza®, the only inhaled ultra rapid-acting mealtime insulin in the U.S.

WESTLAKE VILLAGE, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer Michael Castagna, PharmD, will participate in a Fireside Chat at the H.C. Wainwright 23^rd Annual Global Investment Conference which will be available on demand starting on September 13, 2021. 

Interested parties can access a link to the on demand webcast of the presentation from the Events & Presentations section of the Company’s website at https://investors.mannkindcorp.com/events-and-presentations.  The webcast replay may be accessed at the same location for 14 days.

About MannKind Corporation
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company’s first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. Afrezza is also available by prescription in Brazil, where it is commercialized by the Company’s partner Biomm SA. MannKind was established in 1991, and is headquartered in Westlake Village, Calif., with a manufacturing and R&D facility based in Danbury, Conn. The Company also employs field sales and medical representatives across the U.S. Please visit mannkindcorp.com to learn more.

Contact:
Rose Alinaya, Investor Relations
(818) 661-5000
Email: ir@mannkindcorp.com

FAQ

When will MannKind's CEO participate in the H.C. Wainwright Conference?

CEO Michael Castagna will participate in the Fireside Chat at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021.

How can I access the MannKind Corporation Fireside Chat?

The Fireside Chat will be available on demand and can be accessed through the Events & Presentations section on MannKind's website.

What product does MannKind currently commercialize?

MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the only inhaled ultra rapid-acting mealtime insulin in the U.S.

What is the significance of Afrezza for patients?

Afrezza is significant as it provides an inhaled option for mealtime insulin, offering a rapid-acting alternative for patients with diabetes.

Where is MannKind Corporation headquartered?

MannKind Corporation is headquartered in Westlake Village, California.